Glimisave MV 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2 mg), Metformin (500 mg), and Voglibose (0.2 mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, promoting stable plasma concentrations and improved patient compliance. Glimisave MV 2 is indicated for use in patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in cases of diabetic ketoacidosis, severe infections, or hypersensitivity to any component. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rare allergic reactions. This combination therapy offers a comprehensive approach to managing type 2 diabetes by targeting multiple pathophysiological mechanisms.